These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Double-blind controlled trial with colloidal bismuth subcitrate in the treatment of symptomatic duodenal ulcers with special references to blood and urine bismuth levels. Dekker W; Reisma K Ann Clin Res; 1979 Jun; 11(3):94-7. PubMed ID: 386913 [TBL] [Abstract][Full Text] [Related]
24. Colloidal bismuth subcitrate, ranitidine, and ranitidine plus metronidazole in the treatment of duodenal ulcer and Helicobacter pylori infection: a controlled and prospective study. Huang CK; Chen GH Zhonghua Yi Xue Za Zhi (Taipei); 1993 Jul; 52(1):15-20. PubMed ID: 8364776 [TBL] [Abstract][Full Text] [Related]
30. Histological maturity of healed duodenal ulcers and ulcer recurrence after treatment with colloidal bismuth subcitrate or cimetidine. Pan SA; Liao CH; Lien GS; Chen SH Gastroenterology; 1991 Nov; 101(5):1187-91. PubMed ID: 1936788 [TBL] [Abstract][Full Text] [Related]
31. Treatment of Campylobacter pylori gastritis: a pilot study using pirenzepine dihydrochloride (Gastrozepin) and three formulations of colloidal bismuth subcitrate (De-Nol). Morris A; Brown P; Ali MR; Lane M; Palmer R N Z Med J; 1988 Oct; 101(856 Pt 1):651-4. PubMed ID: 3054641 [TBL] [Abstract][Full Text] [Related]
32. Low dose, short duration therapy for the eradication of Helicobacter pylori in patients with duodenal ulcer. Iser JH; Buttigieg RJ; Iseli A Med J Aust; 1994 Feb; 160(4):192-6. PubMed ID: 7906009 [TBL] [Abstract][Full Text] [Related]
33. Absorption of bismuth from two bismuth compounds before and after healing of peptic ulcers. Hundal O; Bergseth M; Gharehnia B; Andersen KJ; Berstad A Hepatogastroenterology; 1999; 46(29):2882-6. PubMed ID: 10576366 [TBL] [Abstract][Full Text] [Related]
34. Acid, pepsin, and mucus secretion in patients with gastric and duodenal ulcer before and after colloidal bismuth subcitrate (De-Nol). Baron JH; Barr J; Batten J; Sidebotham R; Spencer J Gut; 1986 May; 27(5):486-90. PubMed ID: 3084345 [TBL] [Abstract][Full Text] [Related]
35. [Evaluation of a combination of colloidal bismuth and pirenzepine in duodenal ulcer in non-responders to anti-H2 receptors]. Manca A; Ferraris R; Ghezzo L; Asnaghi G; Ferro GF Minerva Dietol Gastroenterol; 1988; 34(2):135-8. PubMed ID: 3173756 [No Abstract] [Full Text] [Related]
36. Mucosa protectives: sucralfate and colloidal bismuth subcitrate in peptic ulcer disease. Tytgat GN; Nio CY Z Gastroenterol; 1987 Aug; 25 Suppl 3():152-61. PubMed ID: 3660894 [TBL] [Abstract][Full Text] [Related]
37. The safety and efficacy of tripotassium dicitrato bismuthate (De-Nol) maintenance therapy in patients with duodenal ulceration. Dunk AA; Prabhu U; Tobin A; O'Morain C; Mowat NA Aliment Pharmacol Ther; 1990 Apr; 4(2):157-62. PubMed ID: 2104081 [TBL] [Abstract][Full Text] [Related]
38. Colloidal bismuth subcitrate (DE-NOL) and tinidazole healed duodenal ulceration with a low relapse rate due to elimination of Campylobacter pylori. Goodwin CS; Marshall BJ; Blackbourn SJ; Warren JR; Phillips M J Chemother; 1989 Jul; 1(4 Suppl):838-9. PubMed ID: 16312662 [No Abstract] [Full Text] [Related]
39. Randomized clinical trial comparing two one-week triple-therapy regimens for the eradication of Helicobacter pylori infection and duodenal ulcer healing. Forné M; Viver JM; Esteve M; Fernández-Bañares F; Lite J; Espinós JC; Quintana S; Salas A; Garau J Am J Gastroenterol; 1998 Jan; 93(1):35-8. PubMed ID: 9448170 [TBL] [Abstract][Full Text] [Related]